.jpg)
.png)
The National Lipid Association is proud to host Industry Innovations, a podcast series dedicated to showcasing the latest advancements in lipidology. Designed for clinicians, this series offers exclusive insights into cutting-edge science, research breakthroughs, and emerging therapies shaping the future of lipid management.
Each episode, hosted in collaboration with our industry partners, delves deep into the innovations driving progress in cardiovascular health. From exploring novel therapies to understanding groundbreaking clinical trials, Industry Innovations provides valuable knowledge clinicians can apply in their practice to improve patient outcomes.
Stay informed, stay inspired—listen to Industry Innovations and lead the way in lipidology excellence.
Hosted by:
Peter H. Jones, MD, MNLA
Professor Emeritus
Baylor College of Medicine
Houston, TX
Episode 4: Pharmacotherapy Development and Trends in Lipidology: An Expert Discussion
Michael H. Davidson, MD, ABCL, MNLA
NewAmsterdam Pharma,
Naarden, The Netherlands
Lipid Clinic, Pritzker School of Medicine,
University of Chicago,
Chicago, IL, USA
Kevin Maki, PhD, CLS, MNLA
Guest Host
Chief Scientist, Midwest Biomedical Research
Adjunct Professor, Dean’s Eminent Scholar
Indiana University School of Public Health
Bloomington, IN
In this compelling episode of NLA Industry Innovations, host Kevin Maki, PhD, MNLA sits down with renowned lipidologist and clinical researcher Michael Davidson, MD, MNLA to explore the complex world of pharmaceutical development. Together, they unpack the science behind medical therapies—from early-stage innovation to clinical trials—and dive into the strategic decisions that shape which treatments make it to market.
Dr. Davidson offers a behind-the-scenes look at how pharmaceutical companies weigh scientific promise, regulatory pathways, market dynamics, and patient needs when developing new therapies. The conversation also touches on the challenges of balancing innovation with accessibility, and why some promising treatments never reach the shelves.
Whether you're a clinician, researcher, or industry insider, this episode provides valuable insights into the forces driving therapeutic advancement in lipidology and beyond.
Sponsored by NewAmsterdam Pharma
Watch the video of this podcast on YouTube HERE.
Read the publication HERE.
Episode 3: Autoimmune Statin Induced Myopathy: What Everyone Needs to Know
Lisa Christopher-Stine, MD, MPH
Professor of Medicine and Neurology
Director of the Johns Hopkins Myositis Center
Johns Hopkins University
Baltimore, MD
(1).jpg)
Alan S. Brown, MD, MHA, MNLA
Guest Host
Director, Lipid Clinic
Advocate Lutheran General Hospital
Clinical Associate Professor of Medicine
Rosalind Franklin School of Medicine and Science
Loyola University
Chicago, IL
In this episode of Industry Innovations, host Dr. Alan Brown sits down with Dr. Lisa Christopher-Stine, a leading expert in autoimmune muscle disease, to explore the often-overlooked condition of statin-induced autoimmune myopathy. Together, they discuss how to recognize, diagnose, and manage this rare but serious complication, offering key takeaways for clinicians prescribing statins and managing lipid disorders.
Watch the video of this podcast on YouTube HERE.
Sponsored by Werfen
Episode 2: From Innovation to Impact: The RNA Interference Era Begins
Bruce D. Given, MD
Chief Medical Scientist
Arrowhead Pharmaceuticals, Inc.
Pasadena, CA
Dr. Bruce Given shares insights into Arrowhead Pharmaceuticals’ innovative approach to siRNA therapeutics and the company’s growing role in lipid management and cardiovascular care. Hosted by Dr. Peter Jones, this conversation highlights the intersection of clinical need and next-gen molecular science.
Sponsored by Arrowhead Pharmaceuticals
Episode 1: Inflammation and Heart Attacks: A New Frontier in Prevention with LODOCO
Guy L Mintz, MD, FNLA
Director of Cardiovascular Health & Lipidology
Director Lipid Apheresis
Sandra Atlas Bass Heart Hospital
North Shore University Hospital
President Northeast Lipid Association
Associate Professor of Medicine
Zucker School of Medicine
Manhasset, NY
In this episode of Industry Innovations, host Dr. Peter Jones is joined by Dr. Guy Mintz to explore an exciting advancement in cardiovascular care: LODOCO, a low-dose colchicine developed by Agepha Pharma. Backed by robust clinical trial data, LODOCO is an FDA-approved therapy targeting inflammation as a novel approach to reducing the risk of heart attacks.
Learn how inflammation contributes to cardiovascular events and why this groundbreaking therapy is redefining prevention strategies. Dr. Mintz discusses the science, the data, and the potential impact of LODOCO on clinical practice, offering valuable insights for clinicians committed to improving patient outcomes.
Sponsored by Agepha Pharma
This page was last updated: Oct 10, 2025